TYRA250117C30000
- 0.00
- 0.000.00%
TYRA BIOSCIENCES, INC. Newsroom
Tyra Biosciences Insider Sold Shares Worth $409,645, According to a Recent SEC Filing
H.C. Wainwright Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $30
Tyra Biosciences Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
FDA Grants IND Clearance For Tyra Biosciences' TYRA-300
Tyra Biosciences' TYRA-300 Gets US FDA Clearance for Phase 2 Trial in Non-Muscle Invasive Bladder Cancer
Express News | Tyra Biosciences Receives Ind Clearance From FDA to Proceed With Phase 2 Study of Tyra-300 in Non-Muscle Invasive Bladder Cancer (Surf302)
UBS Initiates Coverage On Tyra Biosciences With Buy Rating, Announces Price Target of $28
UBS Initiates TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Announces Target Price $28
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $29
Neumora Therapeutics, XPeng And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans
Piper Sandler Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $33
Tyra Biosciences, Inc. (NASDAQ:TYRA) Shares Could Be 43% Below Their Intrinsic Value Estimate
Tyra Biosciences to Present at Upcoming Investor Conferences
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Cuts Target Price to $29
Tyra Biosciences Analyst Ratings
H.C. Wainwright Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Cuts Target Price to $30
Express News | Tyra Biosciences, Inc. : H.c. Wainwright Cuts Target Price to $30 From $32
Oppenheimer Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $33
TD Cowen Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating